Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.85 |
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.75 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343693 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL9716739 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL9716727 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL5946236 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL2166697 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL1487710 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL1982744 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL15474 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL342965 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL4020128 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043460-A1 | ANHYDROUS COMPOSITION FOR CARING FOR AND/OR MAKING UP KERATIN MATERIALS | L'OREAL (FR) | 2025-03-06 | — | — | WO | claimed |
| US-11603387-B2 | SOCS mimetics for the treatment of diseases | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-03-14 | — | — | US | claimed |
| EP-4138770-A1 | TRANSPARENT SHAMPOO BAR AND METHOD FOR PREPARING THE SAME | Henkel AG & Co. KGaA (DE) | 2023-03-01 | — | — | EP | claimed |
| EP-3096775-B1 | SOCS MIMETICS FOR THE TREATMENT OF DISEASES | UNIV FLORIDA (US) | 2023-01-11 | — | — | EP | claimed |
| CN-115427007-A | Transparent shampoo block and preparation method thereof | 汉高股份有限及两合公司 | 2022-12-02 | — | — | CN | claimed |
| EP-4000627-A1 | TREATMENT OF ABDOMINAL AORTIC ANEURYSM AFTER ITS CLINICAL MANIFESTATION | Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz (ES) | 2022-05-25 | — | — | EP | claimed |
| US-20220062426-A1 | Methods and agents to treat tumor cells and cancer | Wang, Tianxin (US) | 2022-03-03 | — | — | US | claimed |
| WO-2021212404-A1 | TRANSPARENT SHAMPOO BAR AND METHOD FOR PREPARING THE SAME | HENKEL AG & CO. KGAA (DE) | 2021-10-28 | — | — | WO | claimed |
| EP-2427775-B1 | PEPTIDE LIGANDS OF SOMATOSTATIN RECEPTORS | BCN PEPTIDES SA (ES) | 2021-08-11 | — | — | EP | claimed |
| US-20210032304-A1 | FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2021-02-04 | — | — | US | claimed |
| WO-2015083173-A1 | REDUCTION OF INFLAMMATORY DISEASE SYMPTOMS BY SHORT PEPTIDES THAT INHIBIT SIGNALING THROUGH CD28 | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-06-11 | — | — | WO | claimed |
| US-20140134237-A1 | TYPE I INTERFERON MIMETICS AS THERAPEUTICS FOR CANCER, VIRAL INFECTIONS, AND MULTIPLE SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-05-15 | — | — | US | claimed |
| WO-2010151495-A2 | MATERIALS AND METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) | 2010-12-29 | — | — | WO | claimed |
| EP-1065212-A2 | Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines | INSTITUT PASTEUR DE LILLE (FR) | 2001-01-03 | — | — | EP | claimed |
| US-5993823-A | BETWEEN 10 AND 40 AMINO ACIDS AND AT LEAST ONE ANTIGENIC DETERMINANT, ALSO COMPRISING A CHAIN FROM PIMELAUTIDE, TRIMEXAUTIDE, HEXADECANOIC ACID, 2-AMINO-HEXADECANOIC ACID, STEROID GROUPS AND DERIVATIVES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 1999-11-30 | — | — | US | claimed |
| EP-0491628-B1 | Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines | PASTEUR INSTITUT (FR) | 1999-09-29 | — | — | EP | claimed |
| US-5580563-A | Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof | ROCKEFELLER UNIVERSITY, THE | 1996-12-03 | — | — | US | claimed |
| WO-1993022343-A1 | MULTIPLE ANTIGEN PEPTIDE SYSTEM HAVING ADJUVANT PROPERTIES AND VACCINES PREPARED THEREFROM | THE ROCKFELLER UNIVERSITY (US) | 1993-11-11 | — | — | WO | claimed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | claimed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062426-A1 | Methods and agents to treat tumor cells and cancer | TLR9, TLR3, CD47 | SLC6A5 4455/4885NOD1 361/4885ITGB3 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.